Detailed Research on Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. 

Complete report available @ Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017

The molecules developed by companies in Phase II and Preclinical stages are 6 and 13 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease and Toxicology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Idiopathic Pulmonary Fibrosis, Diabetic Retinopathy, Fibrosis, Glioblastoma Multiforme (GBM), Pancreatic Cancer, Cardiovascular Disease, Chemotherapy Effects, Diabetic Macular Edema, Diabetic Nephropathy, Genital Warts (Condylomata Acuminata), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Kidney Fibrosis, Liver Fibrosis, Malabsorption Syndrome, Melanoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease) and Venous Leg Ulcers (Crural ulcer).

The latest report Integrin Alpha V - Pipeline Review, H1 2017, outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Biogen Inc BioMAS Ltd Factor Therapeutics Ltd MedImmune LLC Merck & Co Inc Merck KGaA SciFluor Life Sciences LLC Vascular Pharmaceuticals Inc 

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###